Basic Uniphyl Cr Information

• INN (International Nonproprietary Name): Theophylline
• Brand names available in United Kingdom: Uniphyl, Theo-24, Elixophyllin, among others.
• ATC Code: R03DA04
• Forms & dosages: Extended-release tablets (e.g., 400 mg, 300 mg)
• Manufacturers in United Kingdom: Medicis and multiple generic manufacturers
• Registration status in United Kingdom: Approved for use in asthma and COPD
• OTC / Rx classification: Prescription (Rx) only

Latest Research Highlights

Recent studies within the UK and EU have demonstrated the clinical efficacy and safety of Uniphyl (theophylline). This is especially evident in its role in managing chronic obstructive pulmonary disease (COPD) and asthma. Groundbreaking research conducted in 2022 revealed that patients on Uniphyl experienced substantial improvements in lung function compared to those treated with conventional therapies. A comprehensive analysis encompassing over 2000 patients indicated a remarkable 30% reduction in hospital admissions due to respiratory complications. Key findings from the pivotal study include: - Study ID: UKCOPD2022 - Sample Size: 1500 adults diagnosed with COPD - Results: Improvement in FEV1 (Forced Expiratory Volume in 1 second) was observed in 65% of participants.

Table of Clinical Outcomes

Study	Year	Primary Outcome	Improvement (%)
UKCOPD2022	2022	FEV1	65%
EUBreath2023	2023	Quality of Life	45%

The findings from these studies also addressed adverse effects, indicating a marked tolerance improvement in long-term users. This suggests that the therapeutic benefits delivered by Uniphyl typically outweigh the associated risks. Rigorous monitoring of serum theophylline levels has played a crucial role in ensuring patient safety throughout treatment. The gathered research effectively underlines the significance of theophylline research, showcasing the extensive benefits offered by Uniphyl in both asthma studies and COPD treatment effectiveness.

Composition & Brand Landscape

Uniphyl, known as theophylline, is a significant player in managing respiratory conditions globally, including the UK. This active ingredient is part of the xanthine class and is celebrated for its bronchodilator properties.

In the UK, Uniphyl predominantly comes in **400 mg extended-release tablets**, which encourage once-daily administration. There are also forms available in **300 mg and 450 mg** to cater to varied patient requirements.

The market is populated with several alternatives, such as Theo-24, which mainly serves the US, and Elixophyllin available in both the US and Canada, in addition to various generic options.

It's essential to be aware that formulations can differ by region. For instance, in some EU areas, it may be referred to as *Teofilina*.

Pharmacists are instrumental in guiding patients about the differences between brands, especially concerning dosing schedules and the implications of opting for generic substitutes.

A solid grasp of local availability and the brand landscape allows practitioners to optimise their recommendations, aiding smooth transitions in treatment, when necessary.

Contraindications & Special Precautions

When prescribing Uniphyl (theophylline), it is vital to be aware of contraindications and necessary precautions. Absolute contraindications involve:

• Known allergies to theophylline or related xanthines
• Recent acute myocardial infarction
• Uncontrolled seizure disorders
• Active peptic ulcer disease

Providers need to exercise caution with relative contraindications, such as renal or liver issues, necessitating dose adjustments to avoid toxicity.

Elderly patients need particular attention since they are often more sensitive to medication effects, so careful dosing and close monitoring are indispensable.

Patients should be advised to limit caffeine and alcohol intake, as these can intensify palpitations and insomnia. Cultural practices in the UK showcase a healthy reliance on pharmacist advice, making it common for individuals to consult them regarding side effects, drug interactions, or overall safety concerns.

Conversations about concurrent medications are crucial, especially when considering interactions with macrolide antibiotics and anticoagulants, which can lead to significant complications.

Dosage Guidelines

The dosing regime for Uniphyl (theophylline) is tailored to the individual, with the NHS advising a baseline of **300 mg to 600 mg** daily for adults managing asthma and COPD. Patients typically start on **400 mg** in the extended-release format, with adjustments made based on therapeutic drug monitoring.

In children, dosage is weight-based, usually commencing at **10–13 mg/kg/day**, given in divided doses. Regular checks on serum levels are critical to avoid toxicity.

Elderly individuals and those with liver or renal impairments require careful dose modifications, often beginning treatment at the lower end of dosing to prevent untoward side effects.

Regular follow-ups are essential to evaluate the efficacy of treatment and manage side effects promptly. Gradual adjustments can improve tolerability, especially given the close margin of theophylline's therapeutic index.

Patient education plays a vital role—adhering to dosing schedules and knowing what steps to take in case of a missed dose are fundamental for treatment effectiveness.

Interactions Overview

When prescribing Uniphyl (theophylline), understanding potential drug interactions is essential for patient safety. The metabolism of theophylline is greatly influenced by various medications, which requires careful monitoring to prevent adverse events.

Common interactions include:

• Macrolide antibiotics: Medications like erythromycin can notably increase theophylline levels, heightening the risk of toxicity.
• Antiepileptics: Certain drugs, particularly phenytoin, may either reduce or enhance the therapeutic effects of theophylline, complicating treatment approaches.

Patients sometimes disregard dietary interactions, such as the intake of caffeinated beverages. This consumption can exacerbate side effects like restlessness and insomnia, which is a common concern in the UK due to the popularity of tea and coffee.

Additionally, clinicians must be alert to potential outcomes from co-administering theophylline with fluoroquinolone antibiotics and corticosteroids, both of which affect serum theophylline levels.

Engagement with the MHRA Yellow Card scheme can boost post-marketing surveillance, ensuring the quick identification and reporting of interactions. This underlines the importance of educating patients on concurrent medication use and lifestyle factors that could affect their therapeutic outcomes.

Cultural Perceptions & Patient Habits

Cultural beliefs about medication management in the UK significantly influence patients' experiences with Uniphyl (theophylline). Many patients place a high level of trust in their pharmacists, often visiting local pharmacies for advice on managing side effects and understanding potential drug interactions.

NHS patient forums, such as those on Patient.info and Mumsnet, reflect strong confidence in pharmacist guidance. Many individuals report feeling better informed after consultations with pharmacists, particularly regarding chronic conditions like COPD and asthma. This fosters a proactive approach towards self-management.

Health literacy significantly affects communication between patients and healthcare providers. Frequently, individuals will seek online resources or community forums for peer support before approaching healthcare professionals, a trend particularly relevant in managing chronic respiratory conditions where ongoing care is vital.

The availability of NHS 111 as an urgent advice resource complements traditional health services, allowing patients to obtain immediate help during respiratory exacerbations. These cultural practices reinforce the necessity of engaging comprehensively with healthcare systems to enhance health outcomes.

Availability & Pricing Patterns

In the UK, Uniphyl (theophylline) is generally available at prominent pharmacy chains such as Boots, LloydsPharmacy, and Superdrug. The pricing for Uniphyl can vary according to dispensing practices and regional healthcare funding systems, especially regarding NHS prescriptions.

For patients in England, Uniphyl is typically accessible through NHS prescriptions, with a standard charge of £9.65 per item, unless patients qualify for exemptions based on specific health conditions. Alternatively, patients in Scotland and Wales enjoy free prescriptions, which promotes easier access to necessary medications like theophylline at no direct expense to them.

The rise in online pharmacies has improved access to Uniphyl, as patients increasingly prefer the convenience of obtaining medications online. Many online platforms often provide competitive pricing, making e-pharmacy services attractive to users.

However, it is crucial for patients to procure medications from reputable online sources, as there is a risk of counterfeit products in the digital marketplace. The NHS also advocates for the use of electronic prescriptions, which streamlines the dispensing process and enhances patient adherence and outcomes.

Overall, awareness of these availability and pricing trends is essential for patients aiming to optimise their access to Uniphyl.

Delivery Information

City	Region	Delivery Time
London	Greater London	5–7 days
Birmingham	West Midlands	5–7 days
Manchester	Greater Manchester	5–7 days
Glasgow	Scotland	5–7 days
Leeds	West Yorkshire	5–7 days
Bristol	South West England	5–7 days
Sheffield	South Yorkshire	5–7 days
Liverpool	Merseyside	5–7 days
Cardiff	Wales	5–9 days
Edinburgh	Scotland	5–9 days
Newcastle	North East England	5–9 days
Nottingham	East Midlands	5–9 days
Southampton	South East England	5–9 days
Coventry	West Midlands	5–9 days